

Monoklonale Gammopathien: Neue IMWG-Kriterien und Labortests für die Diagnose, Prognose und Verlaufskontrolle des Multiplen Myeloms

Luca Bernasconi, Esther Mundwiler

Referenzen

1. Rajkumar, S.V., et al., *International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma*. Lancet Oncol, 2014. **15**(12): p. e538-48.
2. Mateos, M.V., et al., *Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma*. N Engl J Med, 2013. **369**(5): p. 438-47.
3. Katzmann, J.A., et al., *Screening panels for detection of monoclonal gammopathies*. Clin Chem, 2009. **55**(8): p. 1517-22.
4. Katzmann, J.A., *Screening panels for monoclonal gammopathies: time to change*. Clin Biochem Rev, 2009. **30**(3): p. 105-11.
5. Dimopoulos, M., et al., *Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3*. Blood, 2011. **117**(18): p. 4701-5.
6. Samaras, P., et al., *Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland*. Swiss Med Wkly, 2015. **145**: p. w14100.
7. Kyrtsolis, M.C., et al., *Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma*. Semin Hematol, 2009. **46**(2): p. 110-7.
8. Larsen, J.T., et al., *Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma*. Leukemia, 2013. **27**(4): p. 941-6.
9. Rajkumar, S.V., et al., *Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance*. Blood, 2005. **106**(3): p. 812-7.
10. Kyle, R.A., et al., *Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management*. Leukemia, 2010. **24**(6): p. 1121-7.

11. Brioli, A., et al., *Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome*. Blood, 2014. **123**(22): p. 3414-9.
12. Bradwell, A., et al., *Prognostic utility of intact immunoglobulin Ig'kappa/Ig'lambda ratios in multiple myeloma patients*. Leukemia, 2013. **27**(1): p. 202-7.
13. Katzmann, J.A., et al., *Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS*. Leukemia, 2013. **27**(1): p. 208-12.